Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma

Background Pancreatic ductal adenocarcinoma (PDAC) has a high fatality rate, with surgery as the only curative treatment. Identification of new biomarkers related to survival may help guide discovery of new pathophysiologic pathways and potential therapeutic targets. As long-chain ceramides have bee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2024-12, Vol.31 (13), p.8725-8733
Hauptverfasser:	Mitchell, Joshua D., Panni, Usman, Fergestrom, Nicole, Toriola, Adetunji T., Nywening, Timothy M., Goedegebuure, S. Peter, Jiang, Xuntian, Mudd, Jacqueline L., Cao, Yin, Ippolito, Joseph, Fields, Ryan C., Hawkins, William G., Peterson, Linda R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Aged Biomarkers, Tumor - blood Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - surgery Ceramide Ceramides - blood Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Mortality Oncology Pancreas Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - surgery Pancreatic Tumors Patients Plasma Prognosis Regression analysis Surgery Surgical Oncology Survival Survival Rate Therapeutic targets Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!